Like most psychiatric disorders, autism spectrum disorders have both a genetic and an environmental component. While previous studies have clearly demonstrated the contribution of in utero (prenatal) environment on autism risk, most of them focused on transient environmental factors. Based on a recent sibling study, we hypothesized that environmental factors could also come from the maternal genome, which would result in persistent effects across siblings.
Introduction
Epidemiological family and twin studies have determined that many psychiatric disorders have both a genetic and an environmental component [Shih, Belmonte, & Zandi, 2004] . Autism spectrum disorders (ASDs) are pervasive developmental disorders, affecting one out of every 88 children aged 8 years in the United States [Autism and Developmental Disabilities Monitoring Network Surveillance Year Principal Investigators and Centers for Disease Control and Prevention, 2012] . They are characterized by deficits in social interaction, restricted interests, and resistance to change [Moldin & Rubenstein, 2006] . Previous studies on recurrence rates of monozygotic twins versus dizygotic twins indicated very high heritability for ASDs [Ronald & Hoekstra, 2011; Schaaf & Zoghbi, 2011] . However, in 70% of ASDs cases, the underlying genetic cause cannot be identified [Schaaf & Zoghbi, 2011] . This suggests a more complex relationship between genetic factors and environmental factors in contributing to the risk of the disorder. Environmental factors in autism include prenatal, perinatal, and postnatal environments. They have been investigated in a number of studies [Folstein & Rosen-Sheidley, 2001; Gardener, Spiegelman, & Buka, 2009] , and recent work suggested that they might have a more important role than previously considered [Hallmayer et al., 2011] .
The effects of prenatal environment on autism risk have been suggested by many studies. One line of evidence comes from family and twin studies: even though both dizygotic twins and full siblings share half of their genome, the recurrence rate in dizygotic twins is around 30% [Hallmayer et al., 2011; Rosenberg et al., 2009] , whereas in nontwin siblings it is 3-14% [Bolton et al., 1994; Constantino, Zhang, Frazier, Abbacchi, & Law, 2010; Sumi, Taniai, Miyachi, & Tanemura, 2006] . This increased risk in dizygotic twins suggests the possibility of the contribution of transient factors in the prenatal environment to the risk of this disorder. Studies also indicated an association between autism with maternal hypothyroidism [Gillberg, Gillberg, & Kopp, 1992; Haddow et al., 1999] , maternal thalidomide use [Miller & Strömland, 1993; Stromland, Nordin, Miller, Akerstrom, & Gillberg, 1994] , maternal valproic acid use [Christianson, Chesler, & Kromberg, 1994; Williams & Hersh, 1997] , maternal alcohol use [Aronson, Hagberg, & Gillberg, 1997; Nanson, 1992] , and maternal viral infection [Stubbs, 1978; Stubbs, Ash, & Williams, 1984] . Association between maternal viral infection and autism was further supported by recent studies using a mouse model, which showed that maternal viral infection can cause behavioral and neuropathological symptoms in offspring [Hsiao, McBride, Chow, Mazmanian, & Patterson, 2012] . Thus, it is clear that prenatal environment contributes to autism risk.
The factors we discussed above have transient influence on the prenatal environment, but it is also possible that some prenatal environmental factors could be a product of the mother's genome (which has permanent influence on prenatal environment): we hypothesize that some genetic variants carried by the mother could increase risk of autism in her children through alteration of the prenatal environment (hypothetical examples could be polymorphisms influencing thyroid levels, uterine nutrient levels, or immune system function). This hypothesis is supported by a recent half-sibling study [Constantino et al., 2012] . The study showed that recurrence rate in maternal half siblings, who would have been exposed to the same maternal genome, was 5.2% (n = 619) while the paternal half-sibling recurrence rate was 0% (n = 55). Even though the sample size of paternal half sibling was very small, this suggested (P < .07, Fisher's exact test) the possibility of some influence on autism risk derived from the mother that persists across multiple siblings.
The mother's genome influences development of the offspring through mechanisms such as maternal genotype effects, maternal-fetal genotype interactions, and parent-of-origin effects (imprinting) [Ainsworth, Unwin, Jamison, & Cordell, 2011] . In fact, a variety of diseases are hypothesized to have contributions from such mechanisms. For example, maternal genotype effects have been implicated in risk of spina bifida in offspring [Jensen, Etheredge, Brown, Mitchell, & Whitehead, 2006] ; human leukocyte antigen (HLA) maternal-fetal genotype matching has been associated with low birth weight [Larizza et al., 2002; Ober et al., 1987] and schizophrenia [Palmer et al., 2006] ; imprinting effects have been implicated in children affected with congenital toxoplasmosis [Jamieson et al., 2008] . Previous authors have referred to such alleles embedded in the maternal genome and increasing the risk of disease in the children as "teratogenic alleles" [Johnson, 2003] . They identified two possible teratogenic alleles in mothers of autism probands, GSTP*A [Williams et al., 2007] and HLA-DR4 [Johnson et al., 2009] . In this paper, we performed a genome-wide search in mothers for such alleles.
We propose and test here a direct approach to examine the contribution of the maternal genotype effects to autism risk using existing data sources: we reexamined the Autism Genetic Resource Exchange (AGRE) [Geschwind et al., 2001 ] dataset by conducting a case-control genomewide association analysis treating mothers of probands as cases and either fathers of probands, or females from an independent dataset, as controls based on a logistic model. Then we repeated this analysis with the Simons Simplex Collection (SSC) [Fischbach & Lord, 2010] .
Methods

Datasets
Discovery stage. Case samples in the discovery stage came from the AGRE. Parents of individuals scored as autistic based on the Autism Diagnostic Interview-Revised were selected from AGRE dataset (mother, n = 572; father, n = 547). For multigenerational pedigrees, one motherfather pair was randomly selected. Self-reported Caucasians were selected from the Illumina Genotype Control Database (iCon) [Illumina iControlDB, 2013] as controls. Caucasian females were selected from the iCon (n = 508). Individuals from both datasets were previously genotyped on the Illumina HumanHap 550 platform for 550,000 single-nucleotide polymorphism (SNPs).
Replication stage. Samples in the replication stage were obtained from the SSC and Study of Addiction: Genetics and Environment (SAGE), a control dataset from an addiction study. In the SSC dataset, individuals were genotyped on either Illumina 1Mv1 or Illumina 1Mv3 Duo Bead array [Sanders et al., 2011] ; in the SAGE dataset, genotyping was performed using Illumina Human 1Mv1_C Beadchips [Bierut et al., 2010] . Individuals from both iCon and SAGE datasets were selected to match the ethnicity of case datasets (mostly Caucasian). While they were not ascertained for autism, we assumed that the prevalence in these two datasets would be no higher than that in the general population (∼1%). Two thousand one hundred seventy-seven individuals were collected from the SSC dataset (mother, n = 1089; father, n = 1088) and 2024 females were collected from the SAGE dataset. Individuals from both datasets were genotyped on the Illumina Human 1M platform.
Quality Control
In each study stage, case and control samples were merged and quality control was performed using PLINK [Purcell et al., 2007] .
Individuals matching the following criteria were excluded:
1. Individuals with genotyping rate <0.1. 2. Individuals whose reported sex did not match with predicted sex (based on chromosome X data).
SNPs matching the following criteria were excluded:
1. SNPs with a maximum per-SNP missing >0.1. 2. SNPs with minor allele frequency <0.05. 3. SNPs that violated Hardy-Weinberg disequilibrium (P-value <0.001).
Sample sizes and number of SNPs in each stage that survived quality control were listed in (Table 1) . Even though samples of the replication stage were genotyped on the Illumina Human 1M platform and we expect about one million SNPs, there were 893,308 SNPs overlapping between SSC dataset and SAGE dataset because of slight differences in chip version. Only about 583,160 SNPs survived the merging and quality control in the replication stage.
Principal Component Analysis
Because population substructure confounds association study, principal component analysis (PCA) was utilized to account for this in our analysis. PCA reduces the genetic variation of samples to a small number of principal components, describing as much variation as possible. In the discovery stage, PCA was done using EIGENSTRAT [ Price et al., 2006] with 10 principal components based on about 50,000 independent SNPs (selected to not be in linkage disequilibrium, LD) extracted from the sample. In most cases, each principal component has a geographical or ethnic interpretation. For example, in (Fig. 1A) , we plotted the distribution of samples on the first versus second principal components. It is clear that the first principal component separated Caucasians from African-Americans, and the second principal component separated Caucasians from Asians. Thus, PCA successfully accounted for the population substructure in our samples. Because the first five principal components explained most of the variation (Fig. 1B ), these were taken as covariates in the association tests to account for population substructure. The same type of PCA was also done for the replication stage samples, and the first five principal components were again used as covariates for the replication association studies.
Genotype Imputation
In order to increase the coverage of the genome, SNP imputations were performed in both discovery and replication stages. Because both our discovery and replication stage samples are composed of various racial groups, imputation of individuals' genotypes in both stages was done with 460 HapMap haplotypes including different racial groups (CEU + YRI + CHB + JPT) from HapMap phase 2 release 22 using MACH [Li, Willer, Ding, Scheet, & Abecasis, 2010] . Using a combination of CEU + YRI + CHB + JPT haplotype panels also have performance advantage at rare SNPs compared with using single haplotype panel [Marchini & Howie, 2010] . Following the criteria described in Wang et al.'s [2009] paper, we removed markers with Rsq <0.3 or posterior probability <0.9. After another round of quality control (same as above), a total of 1,776,310 high-quality SNPs remained in discovery stage, and 1,619,647 SNPs remained in replicate stage.
Association Test Design
A two-step association analysis was conducted on samples of the discovery stage (Fig. 2) and then repeated in the replication stage. Association testing was implemented using PLINK based on a logistic model using the first five principal components from PCA analysis as covariates. In the first association test, AGRE mothers were treated as cases, and AGRE fathers as controls. This test identifies associations from three sources:
1. Alleles more prevalent in mothers of probands (maternal genotype effects). 2. Alleles more prevalent in fathers of probands (paternal genotype effects). 3. Alleles with apparent differences between sexes (e.g., three "SNPs" [e.g., rs12734338] on chromosome 1, in a region homologous to chromosome Y, appear to be 100% "heterozygous" for male and 100% "homozygous" for female as previously reported [Boraska et al., 2012] ).
To identify only those alleles due to maternal genotype effects, a second association test was conducted using the same cases but treating females from iCon as controls. This second test detects any maternal effect alleles, but can also be confounded by batch effects: systematic technical differences between samples genotyped at different times or by different groups. Focusing on only those nominally significant SNPs (P < 0.05) in both tests should remove both batch and sex effects as SNPs associated with a maternal contribution to autism risk should be significant in both tests. We set the threshold for nominally significant SNPs at the level of 0.05 for the initial data exploration. At the end of the analysis, we looked for hits with a combined P-value of 10e-8.
Results
In the discovery stage, 14,454 SNPs were nominally significant (P < 0.05) in both AGRE mothers versus fathers and AGRE mothers versus iCon females (Fig. 3, Table 2 ). The most significant SNP with high concordance across Note. After quality control, there are 561 mothers of probands, 547 fathers of probands, and 508 control females with 503 972 SNPs remaining in the discovery stage, 982 mothers of probands, 1007 fathers of probands, and 743 control females with 583 160 SNPs remaining in the replication stage.
both discovery analyses was rs12431425, located in the intergenic region on 14q21.1 (P = 7.8E-06, odds ratio Figure 3 shows the Manhattan plots for both tests, aligned together by genomic coordinates. As estimated by the CaTS power calculator [Skol, Scott, Abecasis, & Boehnke, 2006] , with our sample size, we had 80% power to detect a susceptibility variant with an allele frequency >0.05 and genotype relative risk >2.63. Because we did not find any common variant that reaches genome-wide significance (P < 10 −8
), a common variant with large effect in the maternal genome is unlikely. However, power analysis suggested that we had less than 11% power to detect common variant (disease allele frequency >0.05) of relatively small effect (genotype relative risk <2). Note that even in autism probands, no alleles with a genotype relative risk of <1.2 have been replicated as genome-wide significant by association testing [Anney et al., 2012] . The two best hits described above (rs12431425 and rs2473147) were not replicated as nominally significant in the replication stage. Association testing of all 1,619,647 SNPs did identify 13,440 that were nominally significant both when SSC mothers were compared with SSC fathers and when they were compared with females from the SAGE collection, but none reaching genomewide significance. Three hundred seventy-three out of the nominally significant 14,454 SNPs from the discovery phase had their significance level raised when combining discovery with replicate stages (by merging the two datasets and then performing genome-wide association study on the combined dataset). The most significant SNP Figure 1B shows the screeplot for PCA analysis for samples in discovery stage. The x-axis is principal component number, and the y-axis is the eigenvalue, which is directly proportional to proportion of variation. From this figure, we can see that the first principal component explains the largest proportion of variation and the proportion of variation explained by each subsequent principal component decreases.
from the joint analysis was rs2670494 (combined P-value for proband mother vs. father test is 5.02E-05, combined P-value for proband mother vs. control female test is 8.95E-05), mapped to the intronic region of spermatogenesis associated 21 (SPATA21). However, SSC dataset was ascertained to contain simplex families, and a substantial fraction of the autism probands in this cohort carry significant de novo mutations [Iossifov et al., 2012; Sanders et al., 2011 Sanders et al., , 2012 . Thus, it was less likely that we would find significant association because of maternal genotype effects in the replication stage.
Discussion
To our knowledge, this is the first genome-wide search for maternal genotype effects in autism. Because we were using datasets that were not collected primarily for this purpose, we took a very conservative approach to our analysis. To eliminate any confounding sex or batch effects, we required alleles from the mothers to reach a nominally significant P-value in two separate comparisons. With these filters, we did not identify any SNP that reached genome-wide significance, and we did not replicate earlier teratogenic alleles [Johnson et al., 2009; Williams et al., 2007] , although we had limited power to detect rare polymorphisms or polymorphisms with smaller effect sizes (OR < 2).However, we did identify some interesting candidate genes near our most significant SNPS such as PDE11A. PDE11A is expressed in the adrenal cortex and catalyzes the hydrolysis of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) [Carney, Gaillard, Bertherat, & Stratakis, 2010] . Mutation of this gene is suggested to affect the size of adrenal gland and levels of multiple hormones such as cortisol [Carney et al., 2010; Ceyhan, Birsoy, & Hoffman, 2012] . Because adrenal gland is the key for stress response and regulates both hormone level and immune system, mutation in PDE11A in mothers could affect children's risk of autism through mechanisms such as hormone regulation or immune response.
Here, we used a logarithmic model for association testing implemented in PLINK because it readily permitted the inclusion of population stratification as a covariate. Using this approach, we only explored maternal genotype effects while in fact the maternal genome could also influence risk of autism in offspring through maternal-fetal genotype interactions and imprinting. For example, HLA maternal-fetal genotype matching has been associated with schizophrenia in a previous study [Palmer et al., 2006] . Although it can be difficult to distinguish each of these three possibilities statistically [Ainsworth et al., 2011] , there are elegant linear models for fitting each [Howey & Cordell, 2012] . However, they currently do not implement the inclusion of covariates for coping with population stratification, which is clearly present in our datasets. It is also worth noting that using PCA to exclude non-Caucasians, rather than to generate covariates, still did not uncover genome-wide significant alleles, although our sample size, and thus our power, was substantially lower with that approach (not shown). For our 10 most significant regions (Table 1) , we used Cordell's linear model, EMIM [Howey & Cordell, 2012] , to determine if our findings are consistent with a maternal genotype effect (Supporting Information Table S2 ). This analysis indicates that any risk attributable to these alleles is most consistent with a maternal genotype effect rather than child genotype effect or imprinting effect.
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